Tang Capital Management TRVI Position
ExitedTang Capital Management exited their position in Trevi Therapeutics, Inc. (TRVI) in Q1 2024, after holding the stock for 2 quarters.
The position was first reported in Q4 2023 and has been tracked across 2 quarterly 13F filings.
2 other tracked funds also hold TRVI.
Short interest stands at 14.7% of float with 12.9 days to cover, indicating significant bearish positioning against the stock.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Full company profile →Short Interest
14.7%
12.9 days to cover
Tang Capital Management TRVI Position History
Frequently Asked Questions
Does Tang Capital Management own TRVI?
No. Tang Capital Management exited their position in Trevi Therapeutics, Inc. (TRVI) in Q1 2024. They previously held the stock for 2 quarters.
How many hedge funds own TRVI?
2 specialist biotech hedge funds currently hold TRVI, including OrbiMed Advisors, Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy TRVI?
Tang Capital Management's position in TRVI was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's TRVI position increasing or decreasing?
Tang Capital Management completely exited their TRVI position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TRVICompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →